PCV24 AN EPIDEMIOLOGICAL EVALUATION OF THE IMPACT OF PERCUTANEOUS CORONARY INTERVENTIONS ON THE LENGTH OF STAY AND MORTALITY OF PATIENTS HOSPITALIZED WITH ACUTE CORONARY SYNDROMES  by Chevalier, P & Lamotte, M
A344 13th Euro Abstracts
those with a history of CVD. CONCLUSIONS: In each subgroup, there was a sub-
stantial improvement in LDL-C, while improvement of TG and HDL-C levels were 
moderate and negligible, respectively. Despite LMT, both single and mixed dyslipid-
emias were prevalent among high risk patients, particularly among those with DM 
and even more so among those with FRS > 20%. While the prevalence and persistence 
of dyslipidemia varied between groups, observations suggest that all may beneﬁ t from 
other types of LMT in addition to statins.
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OBJECTIVES: Antihypertensive agents (AH) have been shown to reduce the risk of 
major cardiovascular (CVD) events. However, there is no large scale effectiveness 
studies which have assessed the relationship between adherence to AH medications 
and major CVD outcomes in high risk individuals that have suffered an ischemic 
stroke. The aim of the study was to evaluate the relationship between AH drug adher-
ence and vascular outcomes in a cohort of older patients hospitalized for an ischemic 
stroke and discharged in the community. METHODS: A cohort of 14,227 patients 
with ischemic stroke was reconstructed from RAMQ and Med-Echo databases. Eli-
gible subjects were 65 years and older and treated with AH agents between 1999 and 
2007. A nested case-control design was used to study major CVD outcomes. Every 
case was matched for age and duration of follow-up. The adherence to AH drugs was 
measured as the proportion of days’ supply of medication dispensed over a deﬁ ned 
period. Conditional logistic regression models were used to estimate the rate ratio of 
vascular events adjusting for covariables. RESULTS: Mean patient age was 75 years, 
54% were male, 23% had diabetes, and 47% had dyslipidemia, 38% had CAD, 6% 
MI and 14% had atrial ﬁ brillation. Adherence to AH agents ≥80% reduced the risk 
of vascular events (RR: 0.70; 0.64–0.77) compared to the one of <80%. Male gender, 
prior CVD, and non adherence to therapies for diabetes and dyslipidemia were risk 
factors. CONCLUSIONS: Higher adherence to AH therapy is linked with a risk 
reduction of vascular events among patients with ischemic stroke.
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OBJECTIVES: The correlation between severity of hypertension and risk of end-stage 
renal disease (ESRD) is well known. However, the impact of antihypertensive drug 
adherence on primary prevention of chronic kidney disease (CKD) has never been 
assessed. Our objective was to evaluate the impact of better adherence to antihyper-
tensive (AH) therapy on ESRD. METHODS: A cohort of 208,128 patients was 
reconstructed using RAMQ and MedEcho databases. Patients were eligible if they 
were between 45 to 85 years of age, had a new diagnosis of hypertension and were 
newly treated with AH drug between 1999 and 2007. a nested case-control design 
was used to study the occurrence of ESRD. Every case of ESRD was matched for age 
and duration of follow-up. Adherence level was assessed as a medication possession 
ratio. Conditional logistic regression models were used to estimate the rate ratio of 
ESRD adjusting for several covariables. RESULTS: Patients were at 65 years old and 
42% male. The mean high adherence level (80%) to AH therapy was 90%. We identi-
ﬁ ed 1026 cases with ESRD during follow-up. High adherence level (80%) to AH 
therapy compared to lower adherence level (<80%) was associated with a reduction 
of ESRD (RR: 0.81; 0.70–0.95). Risk factors for ESRD were CKD, gout, diabetes, 
coronary artery disease, chronic heart failure and peripheral vascular disease. CON-
CLUSIONS: The study suggests that better adherence to AH therapy is associated 
with risk reduction of new onset ESRD in hypertensive population.
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Dronedarone is a new antiarrhythmic drug developed for the treatment of atrial ﬁ bril-
lation (AF). While numerous large cardiovascular (CV) clinical trials have assessed the 
efﬁ cacy of different compounds on morbidity and mortality endpoints, dronedarone 
is the ﬁ rst antiarrhythmic drug for AF for which a large randomized clinical trial 
(ATHENA) was designed to assess morbidity/mortality endpoints. OBJECTIVES: To 
perform an effectiveness analysis using the Number Needed to Treat (NNT) approach 
to compare dronedarone with other CV drugs in avoiding major CV events (CV death, 
CV hospitalization and stroke). METHODS: A literature search for 3 CV active 
medications (statins, angiotensin-converting enzyme inhibitors, angiotensin receptor 
blockers) was performed using PubMed from 1995 to present to identify clinical trials 
with endpoints comparable to those of ATHENA. NNTs were calculated using hazard 
ratios; different lengths of follow up were adjusted to one year, dividing each rate of 
events by the study duration. RESULTS: Twenty clinical trials were identiﬁ ed as 
having at least one endpoint comparable to ATHENA. Based on the ATHENA data, 
the NNT per year of treatment with dronedarone to avoid one “CV death”, one “CV 
hospitalization” and one stroke were 157, 11, and 172, respectively. Dronedarone 
was associated with a lower NNT to avoid a “CV death” compared to ramipril 
(HOPE, NNT = 239), pravastatin (LIPID, NNT = 255), and simvastatin (HPS, NNT 
= 325; 4S, NNT = 167), but a higher NNT vs. candesartan in selected chronic heart 
failure patients (CHARM, NNT = 123). NNTs for dronedarone to avoid one “CV 
hospitalization” and one stroke compared favorably to the other medications evalu-
ated. CONCLUSIONS: Pressure on health care budgets emphasizes the need to dem-
onstrate medical value, notably through NNTs which enable comparisons across 
interventions. Dronedarone has morbidity/mortality data (“CV death”, “CV hospital-
izations” and stroke) that compares favorably in terms of NNT to other CV therapies 
within their respective trial patient populations.
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INFARCTION, INTRACEREBRAL HEMORRHAGE, SUBARACHNOID 
HEMORRHAGE AND TRANSIENT ISCHEMIC ATTACK
Kriszbacher I1, Csoboth I1, Fülöp A2, Boncz I1, Köhalmi A1, Müller Á1, Bódis J1
1University of Pécs, Pécs, Hungary; 2National Meteorological Service, Budapest, Hungary
OBJECTIVES: We have investigated, whether the time of onset of an acute cerebro-
vascular event demonstrates a seasonal variation, and whether it is inﬂ uenced by 
meteorological factors. METHODS: We examined patients admitted to Neurology 
Departments in Hungary between 2005 and 2007 with the diagnose of cerebral infarc-
tion, intracerebral hemorrhage, subarachnoid hemorrhage or transient ischemic attack 
(n = 178,092). Data was collected from the database of the Hungarian National Health 
Insurance Fund based on the International Classiﬁ cation of Diseases. Meteorological 
data was retrieved from the National Meteorology Service. RESULTS: Meteorological 
analysis showed, that an increase in average temperature on the previous day resulted 
in a signiﬁ cant drop of intracerebral hemorrhage incidence during Spring, Summer 
and Autumn (P < 0.01), while in case of cerebral infarction such decrease only 
occurred during Summer and Winter (P < 0.01), and for transient ischemic attack, 
only during Summer (P < 0.01).Examining atmospheric pressure, we found variations 
in case of cerebral infarction, intracerebral hemorrhage and transient ischemic attack. 
Morbidity rates of cerebral infarction increased during Summer, and decreased during 
Winter, whenever average atmospheric pressure values on the preceding day were 
higher (P < 0.01). Decrease in morbidity rates was observed for intracerebral hemor-
rhage and transient ischemic attack (P < 0.01). Considering relative humidity on the 
previous day, a marked variation showed for cerebral infarction during Spring (P < 
0.01), and for intracerebral hemorrhage during Summer (P < 0.01). No relationship 
was found with subarachnoid hemorrhage. CONCLUSIONS: Results reveal, that the 
occurrence cerebrovascular events shows typical variations depending on the season 
of the year, while certain meteorological factors inﬂ uence the development these also.
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OBJECTIVES: To assess what proportion of patients treated with low-dose acetyl-
salicylic acid (ASA) for secondary prevention of cardiovascular events discontinue this 
treatment, and to identify risk factors for discontinuation. METHODS: The Health 
Improvement Network UK primary care database was used to identify individuals 
aged 50–84 years with ≥2 prescriptions of low-dose ASA (75–300 mg/day) in 2000–
2007 (n = 35,639). The study cohort was followed from the ﬁ rst day after the initial 
prescription until the earliest occurrence of one of the following: ASA discontinuation 
(a period of ≥90 days after the last prescription would have been used up [assuming 
full compliance], with no reﬁ ll of the prescription during this time); death; diagnosis 
of an alcohol-related condition or cancer; or the end of the study period. The mean 
follow-up time was 2.5 years. RESULTS: Almost one-third of patients discontinued 
low-dose ASA (n = 11,729; incidence: 13.1 per 100 person-years; 95% conﬁ dence 
interval [CI]: 12.9–13.4). The incidence of discontinuation was higher in the ﬁ rst year 
of follow-up (26.7 per 100 person-years; 95% CI: 26.1–27.3) than the rest of the 
study period (6.8 per 100 person-years; 95% CI: 6.6–7.0). The risk of discontinuation 
was 42–67% higher in patients with an initial indication of unstable angina, ischemic 
heart disease or cerebrovascular disease than those with an initial indication of myo-
cardial infarction. Current use of proton pump inhibitors (PPIs) was associated with 
a signiﬁ cant reduction in the risk of discontinuation (odds ratio [OR]: 0.92; 95% CI: 
0.87–0.98; compared with no PPI use). Individuals taking PPIs from the same time as 
their ASA treatment were at particularly low risk of ASA discontinuation (OR: 0.74; 
95% CI: 0.69–0.79). CONCLUSIONS: Discontinuation of low-dose ASA treatment 
is common, especially in the ﬁ rst year of treatment. Concomitant PPI use reduces the 
risk of ASA discontinuation.
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OBJECTIVES: Randomized clinical trial comparing percutaneous coronary interven-
tions (PCI) and non-invasive treatment acute coronary syndromes mostly favour the 
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invasive approach. The aim of this study was to assess whether in a real life setting 
performing acute PCI would have an impact on outcomes as length of stay (LOS) and 
mortality in patients hospitalized for acute coronary syndromes in Belgium. 
METHODS: The average length of stay (LOS) and mortality among hospitalized 
patients with acute coronary syndrome were estimated using the longitudinal IMS 
Hospital Disease Database (year 2007), including data on 34.3% of Belgian hospital 
beds. Stays were identiﬁ ed based on ICD-9 coding and split in ST-elevated Myocardial 
infarction (STEMI ICD-9: 410 excluding 410.7), non-STEMI (ICD-9: 410.7-411.89) 
and unstable angina (ICD-9: 411.1-411.8-413.0). Invasive procedures were identiﬁ ed 
with ICD-9 codes corresponding to PCI (36.0). First stays in the calendar year were 
examined. Comparisons were performed using a Wilcoxon non-parametrical test for 
LOS and a Chi-square for mortality rates. RESULTS: In ﬁ rst hospitalizations, 3,420 
STEMI, 2,070 non-STEMI and 954 unstable anginas were retrieved from the database, 
with respectively 1,206, 504 and 28 of them being treated invasively. LOS of patients 
undergoing PCI was signiﬁ cantly lower in STEMI (6.0 vs. 9.5 days; P < 0.001) and 
non-STEMI (5.1 vs. 9.5; P < 0.001). Mortality in patients with PCI was lower in both 
STEMI (3.5% vs. 17.2%; P < 0.001) and non-STEMI (0.8% vs. 6.2%; P < 0.001). 
Although LOS and mortality in non-invasively treated patients were lower in hospitals 
without a cathlab compared to hospitals with a cathlab, both parameters were signiﬁ -
cantly higher compared to PCI treated patients. CONCLUSIONS: Although informa-
tion on the baseline characteristics of the different patients is limited, the ﬁ ndings of 
this observational study seem to support randomized clinical trials. Treatment with 
PCI decreases the LOS and the mortality signiﬁ cantly in patients with a myocardial 
infarction.
PCV25
RISK OF STROKE AND PREVENTATIVE STEPS AMONG PATIENTS 
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OBJECTIVES: This study examined stroke risk and prevention among European 
patients diagnosed with atrial ﬁ brillation (AF). METHODS: Data were extracted from 
the European 2008 National Health and Wellness Survey, an annual Internet survey 
of self-reported health care attitudes and behaviors among 52,524 adults in Germany, 
Spain, Italy, the UK, and France. Stroke risk was assessed with CHADS2, an index 
summing the presence of congestive heart failure, hypertension, age of 75 years+, 
diabetes mellitus, and history of prior stroke or transient ischemic attack (the latter 
weighted twice). Low- (CHADS2 = 0), moderate- (1), and high- (2+) risk patients 
reported on what steps, if any, they took to prevent stroke: low fat or low sodium 
diet, regular exercise, smoking cessation, weight loss, blood pressure or cholesterol 
reduction, and use of baby aspirin, aggrenox, coumadin/warfarin, plavix, or other 
medications. RESULTS: Among 508 respondents diagnosed with AF (EU prevalence 
of 0.97%), 198 (39%) were low, 158 (31.1%) moderate, and 152 (29.9%) high in 
risk for stroke. Signiﬁ cant differences emerged in the use of any preventative steps 
among low- (23.7%), moderate- (35.4%), and high- (57.2%) risk patients, P < 0.05. 
High-risk patients were signiﬁ cantly more likely than the low-risk group to take every 
preventative step except exercise—16.2% (low), 17.7% (moderate), 20.4% (high)—
and aspirin use—11.1% (low), 13.3% (moderate), 15.8% (high). For example, cou-
madin/warfarin use was higher among high- (21.1%) vs. moderate- (8.9%) and 
low-risk (3.0%) patients, P < 0.05. CONCLUSIONS: In the EU, 42.8% of diagnosed 
AF patients at high risk for stroke took no preventative steps, and no signiﬁ cant dif-
ferences emerged between risk groups on regular exercise and aspirin use. Only 1 in 
5 high-risk patients took coumadin/waraﬁ n, while many more could beneﬁ t from 
prophylactic anticoagulation therapy. Higher risk correlated with higher prevention, 
but there remains an unmet need for increased targeted treatment of high-risk AF 
patients.
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WITH HIP OR KNEE REPLACEMENT SURGERY AND OF ITS IMPACT ON 
THE AVERAGE LENGTH OF STAY
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OBJECTIVES: Recent clinical trials on the new anti-thrombotic agents have shown 
that the incidence of symptomatic deep venous thrombosis (DVT) and pulmonary 
embolism (PE) in patients undergoing hip or knee replacement ranges between 0.5 
and 2%. This study aimed at assessing the real life incidence of DVT/PE after major 
orthopaedic surgery in Belgian and the impact of these complications on the length 
of stay based on a hospital disease database. METHODS: The incidence of DVT/PE 
and the average length of stay (LOS) among patients hospitalized for hip or knee 
replacement surgery were estimated using the longitudinal IMS Hospital Disease 
Database (year 2007), including data on 34.3% of Belgian hospital beds. Stays were 
searched based on ICD-9-CM codes corresponding to hip replacement (81.51-81.52-
81.53) and knee replacement (81.54-81.55). Occurrence of DVT/PE was identiﬁ ed 
with ICD-9 codes 451.1-451.2-453.4. It was also checked whether selected patients 
were administered low-molecular-weight heparin (LMWH). The impact of a DVT/PE 
complication on LOS was assessed through a Wilcoxon non-parametrical test. 
RESULTS: A total of 9377 stays with hip replacement and 6,978 stays with knee 
replacement were retrieved in the database. More than 99.9% of the patients were 
administered LMWH in both subgroups. The number of stays with a DVT/PE episode 
was respectively equal to 51 and 75 within the 2 subgroups, resulting in an incidence 
of 0.54% in patients with hip replacement and 1.07% in patients with knee replace-
ment. LOS of patients with a DVT/PE episode was more than twice as high after both 
hip (34.2 vs. 15.9 days; P < 0.001) and knee (24.9 vs. 12.0 days; P < 0.001) replace-
ment. CONCLUSIONS: The incidences of symptomatic DVT and PE reported in 
clinical trials could be conﬁ rmed based on this retrospective search. The occurrence 
of DVT/PE doubles LOS in patients undergoing hip or knee surgery.
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OBJECTIVES: This study aimed at synthesizing population-based studies on preva-
lence of hypertension in Nigeria from 1990 to 2009. METHODS: Cochrane library 
and PubMed were searched for similar reviews using ﬁ lters for systematic review. 
General databases as well as subject-speciﬁ c databases were searched for primary 
studies. Manuscripts of appropriate studies were retrieved. Quality assessment scale 
was developed to assess the retrieved manuscript and only eligible studies were 
selected. Formal meta-analysis was not conducted due to heterogeneity of data. 
RESULTS: A total of 55 abstracts were identiﬁ ed, out of which 10 full manuscripts 
were retrieved and used for systematic review. There was an increasing trend in preva-
lence of hypertension. Hypertension prevalence in rural areas increased from 18.7% 
in 2003 to 22.4% in 2007. In urban areas, it increased from 23.4% in 1997 to 27.1% 
in 2007. In studies that combined both rural and urban populations, prevalence of 
hypertension increased from 14.5% in 1994 to 34.8% in 2003. There was gender 
difference with respect to prevalence of hypertension as males had higher prevalence 
of hypertension compare to females. CONCLUSIONS: Prevalence of hypertension 
seems to be on the increase in Nigeria. There is a need to develop strategies to prevent, 
treat, and control hypertension effectively in Nigeria.
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CARDIOVASCULAR RISK FACTORS AMONG ASIAN INDIAN AND 
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OBJECTIVES: Current prevalence of cardiovascular risk factors are lacking among 
Asian Indian adults. This study contributes to our knowledge by examining current 
national estimates for hypertension, high cholesterol, diabetes and obesity among 
Asian Indian and white adults aged 20 years and older, by gender and age group. 
METHODS: Cross-sectional observational study design. Analysis of adults 20 years 
and older surveyed in the National Health Interview Surveys (NHIS 2006–2008) 
(Asian Indian, n = 707, white, n = 51,769). RESULTS: The age-standardized preva-
lence of hypertension among Asian Indian adults is 21%, signiﬁ cantly lower than the 
27% prevalence among white adults. At 27%, high cholesterol is equally prevalent in 
both populations. Diabetes is more prevalent among Asian Indian adults (15% vs. 
7%). Asian Indian men have more than twice the rate of diabetes as white men, (17% 
vs.7%), and Asian Indians aged 65 years and older have a higher prevalence of dia-
betes than older, white adults (28% vs. 17%). Obesity rates for Asian Indian adults 
aged 20–39, 40–64, and 65+ are 10%, 16%, and 16%, respectively. Obesity rates for 
white adults aged 20–39, 40–64, and 65+ are 26%, 34%, and 27%, respectively (p 
< 0.0001 for all but 65+ obesity differences). CONCLUSIONS: The age-standardized 
prevalence rate of high cholesterol is similar among Asian Indian and white adults. 
Hypertension rates are lower among Asian Indians. The prevalence of diabetes is 
higher in the Asian Indian population, disproportionately affecting men and older 
adults. Targeted approaches for diabetes disease treatment and reduction are needed.
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METABOLIC SYNDROME IN ACUTE CORONARY DISEASE PATIENTS IN 
OMAN
Al-Zakwani IS1, Al-Rasadi K1, Sulaiman K2, Panduranga P2
1Sultan Qaboos University, Al-Khoudh, Oman; 2Royal Hospital, Muscat, Oman
OBJECTIVES: To evaluate the prevalence, characteristics, and in-hospital outcomes 
of metabolic syndrome (MS) in acute coronary syndrome (ACS) patients in Oman. 
METHODS: Data were analyzed from 1,392 consecutive patients admitted to 15 
hospitals throughout Oman with the ﬁ nal diagnosis of ACS during May 8, 2006 to 
June 6, 2006 and January 29, 2007 to June 29, 2007, as part of Gulf RACE (Registry 
of Acute Coronary Events). MS was deﬁ ned, as stipulated by the recent ATP-III 
guidelines, as having 3 or more of the following abnormalities: waist circumference 
of ≥94 cm for men and ≥80 cm for women, high triglyceride levels (of ≥150 mg/dL 
(1.7 mmol/L) or drug treatment), low high density lipoprotein cholesterol (HDL-C) 
levels (of <40 mg/dL (1.0 mmol/L) for men and <50 mg/dL (1.3 mmol/L) for females 
or drug treatment), blood pressure (of ≥130 mmHg for systolic and/or ≥85 mmHg for 
diastolic or drug treatment), and blood sugar (of ≥100 mg/dL (≥5.6 mmol/L) or drug 
treatment). RESULTS: The overall prevalence rate of MS in ACS patients in Oman 
was 66% with females being the majority (80% versus 57%; P < 0.001). MS was 
associated with higher median body mass index scores (27 versus 24; P < 0.001), 
diabetics (45% versus 19%; P < 0.001), hyperlipidemia (40% versus 23%; P < 0.001), 
hypertension (62% versus 34%; P < 0.001), renal impairment (9.3% versus 3.4%; P 
< 0.001), killip score >II (13% versus 8%; p = 0.004) and non-ST segment elevation 
